Vyome Holdings Reports Q1 Revenue of $31.59M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: seekingalpha
- Revenue Performance: Vyome Holdings reported Q1 revenue of $31.59 million, indicating stable growth in the market despite industry challenges, showcasing the company's ability to maintain revenue levels.
- Net Loss Overview: For the quarter ended March 31, 2026, the net loss attributable to common shareholders was approximately $963,000, or about $0.15 per basic and diluted share, reflecting the investment pressures faced during the company's expansion phase.
- Cash Flow Status: As of March 31, 2026, the company had approximately $8.8 million in cash and cash equivalents, a significant increase from $5.0 million as of December 31, 2025, indicating improvements in financial management.
- Assets and Equity: Total assets were approximately $10.2 million and total stockholders' equity was about $8.0 million as of March 31, 2026, demonstrating a solid financial structure that lays the groundwork for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIND
Wall Street analysts forecast HIND stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.260
Low
15.00
Averages
15.00
High
15.00
Current: 2.260
Low
15.00
Averages
15.00
High
15.00
About HIND
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vyome Holdings Reports Q1 Revenue of $31.59M
- Revenue Performance: Vyome Holdings reported Q1 revenue of $31.59 million, indicating stable growth in the market despite industry challenges, showcasing the company's ability to maintain revenue levels.
- Net Loss Overview: For the quarter ended March 31, 2026, the net loss attributable to common shareholders was approximately $963,000, or about $0.15 per basic and diluted share, reflecting the investment pressures faced during the company's expansion phase.
- Cash Flow Status: As of March 31, 2026, the company had approximately $8.8 million in cash and cash equivalents, a significant increase from $5.0 million as of December 31, 2025, indicating improvements in financial management.
- Assets and Equity: Total assets were approximately $10.2 million and total stockholders' equity was about $8.0 million as of March 31, 2026, demonstrating a solid financial structure that lays the groundwork for future growth.
See More
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- Strategic Partnership: Vyome has signed an agreement with Impetis Biosciences, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a substantial $57 billion global market, highlighting the company's growth potential in the biopharmaceutical sector.
- Regulatory Progress: Vyome submitted an Orphan Drug Designation application for VT-1953 to the FDA, along with constructive proposals for the next stages of development, indicating the company's proactive approach in advancing critical drug development.
- Strong Financial Position: As of the end of Q1 2026, Vyome reported approximately $8.8 million in cash and cash equivalents while maintaining a clean capital structure with no debt or preferred stock, reflecting prudent financial management and stability.
- Positive Market Response: The company raised approximately $5.29 million through the sale of 1,089,545 common shares at an average price of $5.00, representing a 59.2% premium to the previous day's closing price, demonstrating market confidence in Vyome's future prospects.
See More
Vyome Holdings Reports FY 2025 Financial Results
- Financial Overview: Vyome Holdings reported FY 2025 revenue of $0.32 million, indicating challenges in market performance, and despite having approximately $4.94 million in cash and short-term investments, the company needs to enhance revenue for sustainable growth.
- Cash Position: As of December 31, 2025, the company holds approximately $4.94 million in cash and equivalents, with an additional $5.3 million expected from an ATM agreement in January 2026, ensuring operational funding for the near future.
- Loss Report: The net loss of $10,477,713 primarily reflects one-time merger and financing-related expenses of about $7.7 million, which puts pressure on the company's financial health, necessitating close attention to future cost control measures.
- Research Outlook: The anticipated interim analysis of the pivotal VT-1953 study around mid-2027 presents a potential growth opportunity, although the current financial situation is challenging, successful clinical trials could lead to new avenues for revenue generation.
See More
Vyome Publishes Preclinical Data for VT-1908
- Preclinical Data Release: Vyome Holdings, Inc. published preclinical data in the Journal of Ophthalmic Inflammation and Infection, validating the efficacy and safety of VT-1908 for treating uveitis, highlighting its potential as a steroid alternative to meet the urgent market demand for safe therapies.
- Significant Market Opportunity: Uveitis accounts for 10-15% of blindness cases in developed countries, with an estimated market opportunity of $3 billion by 2032, positioning VT-1908 for a substantial market share if successfully developed.
- Clinical Development Plans: Vyome intends to leverage the India innovation corridor to advance VT-1908 into clinical development in a highly cost-efficient manner, aiming to generate critical human clinical data that could lead to significant value inflection for the company.
- Focus on Core Programs: While advancing the Phase 3 study of VT-1953, Vyome maintains its capital deployment plan unchanged, ensuring resources are concentrated on the treatment of malignant fungating wounds, which represents a $2.2 billion market opportunity in the U.S.
See More
Harvest Announces 2025 ETF Reinvested Distributions
- Annual Reinvested Distributions: Harvest Portfolios Group has announced the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The distributions will be reported as taxable, which will increase each unitholder's adjusted cost base, impacting future tax handling and ensuring investors are aware of their tax responsibilities.
- Distribution Details Update: All final reinvested capital gain and income distributions for Harvest ETFs are reported as zero, reflecting the company's cautious strategy in the current market environment aimed at protecting investor interests.
- Enhanced Information Transparency: Harvest commits to reporting the actual taxable amounts and nature of distributions to brokers through CDS in early 2026, enhancing transparency and aiding investors in making informed decisions.
See More
Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year
- Reinvestment Distribution Announcement: Harvest Portfolios Group Inc. announces the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged.
- Tax Implications Explained: The distributions will be reported as taxable, expected to be communicated to brokers through CDS in early 2026, which will increase each unitholder's adjusted cost base and impact future tax considerations.
- Distribution Details Update: All Harvest ETFs report zero reinvested capital gain and income distributions, indicating no distributable earnings for the year, which may affect investor return expectations.
- Record Date Set: December 31, 2025, is established as the ex-dividend date for all unitholders of record, ensuring investors are informed of distribution details to make timely investment decisions.
See More
Vyome Holdings Reports Q1 Revenue of $31.59M
- Revenue Performance: Vyome Holdings reported Q1 revenue of $31.59 million, indicating stable growth in the market despite industry challenges, showcasing the company's ability to maintain revenue levels.
- Net Loss Overview: For the quarter ended March 31, 2026, the net loss attributable to common shareholders was approximately $963,000, or about $0.15 per basic and diluted share, reflecting the investment pressures faced during the company's expansion phase.
- Cash Flow Status: As of March 31, 2026, the company had approximately $8.8 million in cash and cash equivalents, a significant increase from $5.0 million as of December 31, 2025, indicating improvements in financial management.
- Assets and Equity: Total assets were approximately $10.2 million and total stockholders' equity was about $8.0 million as of March 31, 2026, demonstrating a solid financial structure that lays the groundwork for future growth.
See More
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- Strategic Partnership: Vyome has signed an agreement with Impetis Biosciences, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a substantial $57 billion global market, highlighting the company's growth potential in the biopharmaceutical sector.
- Regulatory Progress: Vyome submitted an Orphan Drug Designation application for VT-1953 to the FDA, along with constructive proposals for the next stages of development, indicating the company's proactive approach in advancing critical drug development.
- Strong Financial Position: As of the end of Q1 2026, Vyome reported approximately $8.8 million in cash and cash equivalents while maintaining a clean capital structure with no debt or preferred stock, reflecting prudent financial management and stability.
- Positive Market Response: The company raised approximately $5.29 million through the sale of 1,089,545 common shares at an average price of $5.00, representing a 59.2% premium to the previous day's closing price, demonstrating market confidence in Vyome's future prospects.
See More
Vyome Holdings Reports FY 2025 Financial Results
- Financial Overview: Vyome Holdings reported FY 2025 revenue of $0.32 million, indicating challenges in market performance, and despite having approximately $4.94 million in cash and short-term investments, the company needs to enhance revenue for sustainable growth.
- Cash Position: As of December 31, 2025, the company holds approximately $4.94 million in cash and equivalents, with an additional $5.3 million expected from an ATM agreement in January 2026, ensuring operational funding for the near future.
- Loss Report: The net loss of $10,477,713 primarily reflects one-time merger and financing-related expenses of about $7.7 million, which puts pressure on the company's financial health, necessitating close attention to future cost control measures.
- Research Outlook: The anticipated interim analysis of the pivotal VT-1953 study around mid-2027 presents a potential growth opportunity, although the current financial situation is challenging, successful clinical trials could lead to new avenues for revenue generation.
See More
Vyome Publishes Preclinical Data for VT-1908
- Preclinical Data Release: Vyome Holdings, Inc. published preclinical data in the Journal of Ophthalmic Inflammation and Infection, validating the efficacy and safety of VT-1908 for treating uveitis, highlighting its potential as a steroid alternative to meet the urgent market demand for safe therapies.
- Significant Market Opportunity: Uveitis accounts for 10-15% of blindness cases in developed countries, with an estimated market opportunity of $3 billion by 2032, positioning VT-1908 for a substantial market share if successfully developed.
- Clinical Development Plans: Vyome intends to leverage the India innovation corridor to advance VT-1908 into clinical development in a highly cost-efficient manner, aiming to generate critical human clinical data that could lead to significant value inflection for the company.
- Focus on Core Programs: While advancing the Phase 3 study of VT-1953, Vyome maintains its capital deployment plan unchanged, ensuring resources are concentrated on the treatment of malignant fungating wounds, which represents a $2.2 billion market opportunity in the U.S.
See More
Harvest Announces 2025 ETF Reinvested Distributions
- Annual Reinvested Distributions: Harvest Portfolios Group has announced the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged, thereby maintaining asset stability for investors.
- Tax Implications Explained: The distributions will be reported as taxable, which will increase each unitholder's adjusted cost base, impacting future tax handling and ensuring investors are aware of their tax responsibilities.
- Distribution Details Update: All final reinvested capital gain and income distributions for Harvest ETFs are reported as zero, reflecting the company's cautious strategy in the current market environment aimed at protecting investor interests.
- Enhanced Information Transparency: Harvest commits to reporting the actual taxable amounts and nature of distributions to brokers through CDS in early 2026, enhancing transparency and aiding investors in making informed decisions.
See More
Harvest Announces Final Annual Reinvested Distributions for 2025 Tax Year
- Reinvestment Distribution Announcement: Harvest Portfolios Group Inc. announces the final annual reinvested distributions for its ETFs for the 2025 tax year, with all distributions being non-cash, ensuring that the number of units held and the net asset value of the ETFs remain unchanged.
- Tax Implications Explained: The distributions will be reported as taxable, expected to be communicated to brokers through CDS in early 2026, which will increase each unitholder's adjusted cost base and impact future tax considerations.
- Distribution Details Update: All Harvest ETFs report zero reinvested capital gain and income distributions, indicating no distributable earnings for the year, which may affect investor return expectations.
- Record Date Set: December 31, 2025, is established as the ex-dividend date for all unitholders of record, ensuring investors are informed of distribution details to make timely investment decisions.
See More
